New Brain Stent Silences Debilitating Tinnitus in First Human Trial

SAN JOSE, CA – March 09, 2026 – In a significant step forward for neurovascular medicine, medical device company VS3 Medical, Inc. has announced that the first patients in a first-in-human clinical trial experienced immediate relief from debilitating symptoms after receiving a novel brain stent. The device, known as the VS3 Medical™ Stent System, is designed to treat symptomatic venous sinus stenosis, a condition that can cause a persistent, tormenting “whooshing” sound in the ears, severe headaches, and vision loss.

The initial procedures, part of an international feasibility study, resulted in the complete resolution of pulsatile tinnitus for all patients, who were then discharged neurologically intact within 24 hours. These promising early results, presented at the 2026 Society of Neuroinventional Surgery (SNIS) Cerebral Venous and CSF Disorders Summit, signal a potential paradigm shift for a patient population that has long struggled with limited and imperfect treatment options.

The Unseen Struggle of Venous Sinus Stenosis

For thousands of individuals, the world is not a quiet place. They live with a constant, rhythmic sound synchronized to their own heartbeat, a condition known as pulsatile tinnitus. This is often a primary symptom of symptomatic venous sinus stenosis (SVSS), a disorder characterized by the narrowing of the large veins responsible for draining blood from the brain. When these critical drainage pathways become constricted, pressure can build inside the head, leading to a cascade of debilitating effects.

Beyond the maddening internal sound, patients with SVSS frequently suffer from idiopathic intracranial hypertension (IIH), a condition marked by severe headaches and papilledema—swelling of the optic nerve that can lead to progressive, irreversible vision loss. The diagnostic journey is often a frustrating odyssey, with patients enduring years of symptoms before receiving an accurate diagnosis. First-line treatments typically involve medications like diuretics, but these can come with significant side effects and are not always effective.

For more severe cases, physicians have turned to venous sinus stenting, a minimally invasive procedure to prop open the narrowed vein. However, a major challenge has been the lack of a purpose-built tool. Neurointerventionalists have had to rely on “off-label” use of stents originally designed for arteries in the neck or other parts of the body. While often effective, these devices are not optimized for the unique, delicate, and often tortuous anatomy of the brain's venous sinuses, making procedures technically challenging and sometimes requiring multiple stents.

A Purpose-Built Solution for a Complex Problem

VS3 Medical, a private company founded in 2022, aims to solve this problem with its investigational VS3 Medical Stent System. The company's mission is to deliver a solution engineered from the ground up to address the specific anatomical and hemodynamic challenges of the dural venous sinuses.

“Patients who suffer from symptomatic venous sinus stenosis often struggle for years before they are appropriately identified,” said Dr. Matthew Amans, an interventional neuroradiologist and the founder of VS3 Medical, in the company's announcement. “We have developed a device that is designed specifically to address the unique anatomy and hemodynamics of their condition.”

The initial clinical experience seems to validate this approach. Dr. Robert Fahed, an investigator in the first-in-human study and an interventional neuroradiologist at The Ottawa Hospital in Canada, described the device as a “potential breakthrough.”

“The VS3 Medical stent was easily deployed with high precision from the torcula to the sigmoid sinus and conformed without distorting the anatomy,” Dr. Fahed stated. He noted that the new technology could simplify what is traditionally a complex and difficult procedure, potentially “eliminating the need for multiple stents and angioplasty after stenting.” This suggests a future where procedures are not only more effective but also safer and more efficient for both patient and physician.

Navigating the Path from Trial to Treatment

The announcement marks the beginning, not the end, of a rigorous clinical journey. The current first-in-human study is a prospective, multi-center feasibility trial with sites in Canada and Australia. Its primary goal is to evaluate the safety, efficacy, and performance of the stent system at three months post-procedure. To ensure objectivity, the study employs both an independent core lab to analyze results and a data safety monitoring board to oversee patient welfare.

This methodical approach is crucial for bringing a novel Class III medical device to market. “First-in-human” is the initial step in a multi-stage process that will eventually require larger, pivotal trials to generate the robust clinical evidence needed for regulatory approval from bodies like the U.S. Food and Drug Administration (FDA) and Health Canada.

VS3 Medical’s leadership has affirmed its dedication to this process. “I am thrilled to be a part of the VS3 team as we work to advance this important technology and generate meaningful clinical evidence,” said Thomas C. Wilder, chief executive officer of VS3 Medical. “We are committed to executing a multi-year strategy, involving a series of prospective clinical studies, aimed at demonstrating the safety and clinical utility of the purpose-built VS3 Medical Stent System for this important patient population.”

This long-term commitment is backed by a cadre of premier medical investors, including U.S. Venture Partners, Santé Ventures, Gilde Healthcare, and Aperture Venture Partners. Such significant financial backing for a relatively young company underscores the perceived value of its technology and the size of the unmet need it aims to address within the multi-billion-dollar neurovascular device market. For patients who have been waiting for a solution, this first successful step provides a powerful and long-awaited glimmer of hope.